GC Therapeutics (GCTx), a U.S.-based biotechnology company, has secured $65 million in funding from Mubadala Capital and other global investors. This funding aims to develop therapies based on induced pluripotent stem cells (iPSC).
Several other biotechnology companies have entered the iPSC space, which are derived from a person’s skin or blood cells. In August 2023, New York-based BlueRock Therapeutics signed a collaboration agreement with bit.bio to discover and manufacture iPSC-derived regulatory T cell-based therapies. bit.bio has its own opti-ox precision cell programming technology which is used for controlling the expression of transcription factor combinations within cell therapies.
Read the article in
- إعلان -
